Conducted an in-depth analysis of Medicare Part B spending on Immune Globulin (IgG) drugs to identify high-cost brands and assess their economic impact on beneficiaries and the program in SAS Enterprise Guide.

Forecasted spending trends for top IgG drugs and provided cost-saving recommendations by identifying cost-effective alternatives within therapeutic categories.

Performed benchmarking and spending ratio analyses to highlight key drivers of increased costs, focusing on brands like Gammagard Liquid, Gammaked, Privigen, and Octagam.

Proposed policy interventions and cost-containment strategies to reduce out-of-pocket expenses for vulnerable beneficiaries while ensuring CMS program sustainability
